Conditional survival and excess mortality after high - dose therapy with
autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.
A national study on conditional survival, excess mortality and second cancer after high dose therapy with
autologous stem cell transplantation for non-Hodgkin lymphoma.
Not exact matches
Autologous hematopoietic
stem cell transplantation (AHSCT) has been investigated as a treatment
for aggressive MS, the rationale
for which is immune reconstitution.
Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist
for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic
stem cells to the bloodstream
for collection and subsequent
autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
High - Dose Chemotherapy Plus Transplant Not Recommended
for DLBCL: The results of an Italian study report that treatment of high - risk diffuse large B -
cell lymphoma (DLBCL) with abbreviated course of rituximab dose - dense chemotherapy plus high - dose cytarabine, mitoxantrone, and dexamethasone (R - MAD) plus carmustine, etoposide, cytarabine, and melphalan (BEAM) plus
autologous stem cell transplantation compared with a full course of rituximab dose - dense chemotherapy did not improve overall survival.
CRP Levels Before Transplant Linked With Survival in Multiple Myeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an
autologous stem cell transplantation (ASCT)
for multiple myeloma experienced a worse overall survival (OS) rate.
Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation)
for patients with multiple myeloma awaiting
autologous haematopoietic
stem cell transplantation?